



GENOMICS | GENETICS | R&D | DIAGNOSTIC TESTS

MOLECULAR COMBING TO BE USED BY NIH'S SCIENTISTS AS A TOOL FOR CANCER RESEARCH AND DRUG SCREENING

Bagneux (France) -- GENOMIC VISION (FR0011799907 – GV), a biotechnology company developing molecular and Artificial Intelligence tools to control quality and safety of genetically modified genome, announce the acquisition of the molecular combing platform by the Developmental Therapeutics Branch at the National Cancer Institute (NCI) within the NIH based in Bethesda. The FiberComb® and FiberVision® are going to be used to study the perturbation of the DNA replication process in cancer cells. Also, the kinetics of the replication in specific target genes is the goal that will be achieved by using of the GENOMIC VISION platform FiberVision®.

After several years of use and a technical benchmark versus other tools for genome analysis, the NIH has now decided to acquire a full platform.

(https://ccr.cancer.gov/news/inthejournals/itj_Fu; <https://ccr.cancer.gov/news/milestones-2019/article/keeping-dna-replication-in-check>; <https://ccr.cancer.gov/news/article/new-study-characterizes-proteins-role-in-regulating-dna-replication-in-human-cancer-cells>)

The molecular combing helps researcher in the Developmental Therapeutic Branch to find answer for the diverse regulation of the DNA replication in cancer cells. The unique GV technology allows to distinguish the kinetics of the replication forks upon drug treatment or protein modifications. It also allows to visualize how the replication is maintained in cancer cells by displaying the origins of replication.

Aaron Bensimon, co-founder and CEO of Genomic Vision stated: *"We are confident that the NIH choose to use Molecular Combing for its internal research activities and will result in a better understanding of mechanisms of actions of many drugs. The use of GV read-out platform (FiberVision®) coupled with specific Artificial Intelligence algorithms will allow NCI's researchers to go faster in their research programs and to lead to precise conclusions of their different experiments.*

NCI scientists do an incredible work in the cancer research. The work of some of the senior scientists is focused on the DNA replication kinetics in human cells and the different regulation in cancer cells (Zhang, Y., Nat. Commun.). Our technology is the most appropriate tool to promote and improve their research with high precision and fast results. Indeed, the FiberVision®, and the whole GENOMIC VISION platform, are the proper tools to bring deep understanding of the DNA replication kinetics in cancer cells. They can easily study differences in the forks' speeds, stability, symmetry, the distance between the origins or replication or the firing of new origins and the resection of the forks, even upon protein modification. The use of all these parameters brings more details on the function of some proteins in cancer cells. Furthermore, GENOMIC VISION platform helps to better identify and discriminate between compounds against these proteins that are regulated differently in cancer cells."

ABOUT GENOMIC VISION

Genomic Vision is a biotechnology company developing molecular and Artificial Intelligence tools to control quality and safety of genetically modified genome in particular in genome editing technologies and biomanufacturing processes.

Genomic Vision proprietary molecular tools-provide robust quantitative measurements that are needed to enable high confidence characterization of DNA alteration in the genome. These tools are currently use for monitoring DNA replication in cancerous cell, for early cancer detection and the diagnosis of genetic diseases.

Based near Paris, in Bagneux, the Company has approximately 30 employees. GENOMIC VISION is a public listed company listed in compartment C of Euronext's regulated market in Paris (Euronext: GV - ISIN: FR0011799907).

For further information, please visit www.genomicvision.com

ABOUT THE NCI

The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that comprise the Department of Health and Human Services (HHS). NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for cancer research and training. The National Cancer Act of 1971 broadened the scope and responsibilities of NCI and created the National Cancer Program. Over the years, legislative amendments have maintained NCI authorities and responsibilities and added new information dissemination mandates as well as a requirement to assess the incorporation of state-of-the-art cancer treatments into clinical practice.

NCI coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer.

CONTACTS

Genomic Vision

Aaron Bensimon
Co-fondateur et Président du Directoire
Tél. : +33 1 49 08 07 50
investisseurs@genomicvision.com

Ulysse Communication

Bruno Arabian
Tel.:+33142682970
barabian@ulyesse-communication.com

NewCap

Investor Relations / Strategic Communications
Dušan Orešanský / Emmanuel Huynh
Tél. : +33 1 44 71 94 92
gv@newcap.eu



Member of CAC® Mid & Small, CAC® All-Tradable and EnterNext® PEA-PME 150 indexes

FORWARD LOOKING STATEMENT

This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the "Risk Factors" section of the reference document dated March 29, 2019 filed with the AMF under reference number R19-004, available

on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements. This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions